Accelerate to Discover
Related topics
Early fetal sex determination using micro-volume of maternal plasma
Jun 16, 2018
A qPCR-based assay, SneakPeek Early Gender Test (Gateway Genomics) has been developed to determine fetal sex as early...
3R Compliant drug development studies
Jun 8, 2018
In preclinical imaging, magnetic resonance imaging (MRI) can be an attractive alternative to researchers who have...
Kinase study of cytotoxicity voted paper of the year.
Jun 6, 2018
Society of Toxicology voted a xCELLigence based paper the Paper of the Year. The study of cytotoxicity was done using...
xCELLIgence webinar: label-free real-time cell analysis technology for Immuno-Oncology
Jun 5, 2018
Cancer immunotherapies harness and enhance the innate power of the immune system to eliminate cancer cells and have...
Heterodimeric compounds with dual-targeting active against both HIV and tuberculosis.
Jun 4, 2018
Search for dual action drugs against both HIV and Tuberculosis has lead to the creation of heterodimeric compounds with...
Mutual destruction of deep Lung tumor tissues by nanodrug‐conjugated and CQ1 imaging cytometer
Jun 1, 2018
Lung cancer is a highly malignant tumor, and targeted delivery of anti‐cancer drugs to deep lung tumor tissue remains a...
Registering FDG/PET mouse and AMYViD/PET-CT rat studies to brain VOI atlases
May 22, 2018
Preclinical NeuroPET is employed widely in studies of stroke, ischemia, addiction and eurodegenerative diseases. In...
Cobalt (II) ions and nanoparticles induce macrophage retention by ROS-mediated down-regulation
May 21, 2018
Adverse tissue responses to metal wear and corrosion products from CoCr alloy implants remain a great challenge to...
Mar 22, 2016
The mutations driving cancer create clonal populations that differ not just between cancer patients, but within individual tumors. These mutations contain small but significant populations which may survive treatment and metastasize. The only method to get a complete picture of tumor clonality is by sequencing single cells.
In this webinar, you will learn how you can make breakthrough discoveries in your research using single-cell DNA Sequencing. Dr. Ioannis Ragoussis of McGill University will share his research using single-cell whole exome sequencing to reveal the true heterogeneity and cell lineages present in triple negative breast cancer.
Related technologies: Automated Single-cell Genomics
Brand profile
Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.
More info at:
www.fluidigm.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
